Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Prospective Multicentre Validation of a Landmark Machine Learning Model for ICU Mortality in Neurocritical Care (LANDMARK-ICU)

11 november 2026 bijgewerkt door: Han Chen, Fujian Provincial Hospital

A Prospective Multicentre Observational Study Validating a Landmark-Based Machine Learning Model for Dynamic Prediction of Mortality in Patients Receiving Continuous Intracranial Pressure Monitoring

Mortality prediction in neurocritical care relies on scores computed at admission, which cannot update as the clinical course evolves. We previously developed a landmark-based machine learning model that converts hourly physiological data, including intracranial pressure, into an updating risk of death. The model was developed in a large public database and validated retrospectively in a second, independent one. This prospective multicentre study will test the model in consecutive patients at participating hospitals in Fujian Province, China. Physiological data will be collected as part of routine care. The model will generate risk estimates that are recorded for analysis but not shown to treating clinicians, and no treatment decision will be influenced by the study. The primary analysis will assess discrimination and calibration of the model for death during the intensive care stay. Secondary analyses will compare the model with severity scores in routine use and examine performance by aetiology.

Studie Overzicht

Gedetailleerde beschrijving

Model development used the Medical Information Mart for Intensive Care IV database and external validation used the eICU Collaborative Research Database. Both analyses were retrospective and are not part of this registration. This registration covers the prospective multicentre validation only. Inclusion requires age 18 years or older, continuous intracranial pressure monitoring for at least 24 hours, and a diagnosis of traumatic brain injury, aneurysmal subarachnoid haemorrhage or intracerebral haemorrhage. The model uses seven hourly physiological channels with observation masks and elapsed-time features. The primary endpoint is death during the intensive care stay; 28-day mortality, length of stay and Glasgow Outcome Scale at 6 months are secondary. The sample size of 100 patients follows the approved protocol, which assumed area under the curve 0.80 with alpha 0.05 and beta 0.20.

Studietype

Observationeel

Inschrijving (Geschat)

100

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

    • Fujian
      • Fuzhou, Fujian, China
        • Fujian Provincial Hospital
      • Fuzhou, Fujian, China
        • First Affiliated Hospital of Fujian Medical University
      • Quanzhou, Fujian, China
        • Hui'an County Hospital
      • Quanzhou, Fujian, China
        • Second Affiliated Hospital of Fujian Medical University
      • Quanzhou, Fujian, China
        • Shishi City Hospital
      • Zhangzhou, Fujian, China
        • Zhangzhou Municipal Hospital

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 90 jaar (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Bemonsteringsmethode

Kanssteekproef

Studie Bevolking

Adults in intensive care units of participating hospitals who require continuous intracranial pressure monitoring after acute brain injury.

Beschrijving

Inclusion Criteria:

  • Age 18 years or older
  • Continuous intracranial pressure monitoring for at least 24 hours
  • Diagnosis of traumatic brain injury, aneurysmal subarachnoid haemorrhage or intracerebral haemorrhage
  • Written informed consent from the patient or a legal representative

Exclusion Criteria:

  • Incomplete or unusable intracranial pressure recordings
  • Loss to follow-up or unavailable outcome information
  • Pre-existing severe neurological disease that would confound assessment

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Observatiemodellen: COHORT
  • Tijdsperspectieven: PROSPECTIVE

Cohorten en interventies

Groep / Cohort
Interventie / Behandeling
Neurocritical care cohort

Consecutive patients receiving continuous intracranial pressure monitoring, contributing to the risk set at each landmark.

Observational application of a fixed prediction model to hourly physiological data; no treatment is assigned or withheld.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Area under the receiver operating characteristic curve (range 0 to 1) for death during the intensive care stay at the 24-hour landmark
Tijdsspanne: 24 hours after intensive care admission, with the outcome followed to intensive care unit discharge or day 28

Discrimination of the locked landmark model, quantified as the area under the receiver operating characteristic curve, where 0.5 indicates no discrimination and 1.0 perfect discrimination. Death is ascertained from the medical record and the curve is estimated with a 95% confidence interval

24 hours after intensive care admission, with the outcome followed to intensive care unit discharge or day 28

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Area under the receiver operating characteristic curve (range 0 to 1) for death during the intensive care stay at the 48-hour and 72-hour landmarks
Tijdsspanne: 48 and 72 hours after intensive care admission, with the outcome followed to intensive care unit discharge or day 28

Same measurement as the primary outcome, estimated separately at the 48-hour and 72-hour landmarks with 95% confidence intervals

48 and 72 hours after intensive care admission, with the outcome followed to intensive care unit discharge or day 28
Calibration slope (dimensionless) of the landmark model at the 24-, 48- and 72-hour landmarks
Tijdsspanne: 24, 48 and 72 hours after intensive care admission

Slope obtained by logistic regression of the observed outcome on the logit of the predicted risk; a value of 1 indicates perfect calibration, below 1 indicates over-fitting and above 1 under-fitting.

24, 48 and 72 hours after intensive care admission
Brier score (range 0 to 1) of the landmark model at the 24-, 48- and 72-hour landmarks
Tijdsspanne: 24, 48 and 72 hours after intensive care admission

Mean squared difference between predicted risk and observed outcome, where lower values indicate better overall performance.

24, 48 and 72 hours after intensive care admission
Difference in area under the receiver operating characteristic curve (range -1 to 1) between the landmark model and the centre-recorded APACHE II score
Tijdsspanne: 24, 48 and 72 hours after intensive care admission

Paired difference in discrimination, computed as model area under the curve minus APACHE II area under the curve on the same patients, with 95% confidence interval; negative values indicate the model discriminates worse than APACHE II

24, 48 and 72 hours after intensive care admission
Net benefit (dimensionless) of the landmark model from decision-curve analysis at the 24-hour landmark
Tijdsspanne: 24 hours after intensive care admission

Net benefit computed across threshold probabilities from 0.05 to 0.50, compared with the strategies of treating all patients and treating none

24 hours after intensive care admission
Area under the receiver operating characteristic curve (range 0 to 1) by primary diagnosis at the 24-, 48- and 72-hour landmarks
Tijdsspanne: 24, 48 and 72 hours after intensive care admission

Discrimination estimated separately for traumatic brain injury, aneurysmal subarachnoid haemorrhage and intracerebral haemorrhage, reported descriptively because stratum sizes are expected to be small

24, 48 and 72 hours after intensive care admission
28-day all-cause mortality, as specified in the approved protocol
Tijdsspanne: 28 days after intensive care admission
28 days after intensive care admission
Length of intensive care stay
Tijdsspanne: From intensive care admission to intensive care unit discharge, up to 28 days

Duration of intensive care stay in days, right-censored at day 28 for patients still in intensive care

From intensive care admission to intensive care unit discharge, up to 28 days
Glasgow Outcome Scale score (range 1 to 5, higher is better) at 6 months
Tijdsspanne: 6 months after intensive care admission

Glasgow Outcome Scale, an ordinal scale from 1 (death) to 5 (good recovery), with higher scores indicating better outcome; assessed by telephone or outpatient follow-up

6 months after intensive care admission

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

1 december 2026

Primaire voltooiing (Geschat)

12 december 2027

Studie voltooiing (Geschat)

1 januari 2028

Studieregistratiedata

Eerst ingediend

7 november 2026

Eerst ingediend dat voldeed aan de QC-criteria

11 november 2026

Eerst geplaatst (Werkelijk)

17 november 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

17 november 2026

Laatste update ingediend die voldeed aan QC-criteria

11 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Beschrijving IPD-plan

De-identified individual participant data will not be shared publicly because small centre volumes could permit re-identification. The model specification, analysis code and summary results will be published.

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren